SEARCH

SEARCH BY CITATION

Disclaimer: Supplementary materials have been peer-reviewed but not copyedited.

FilenameFormatSizeDescription
eji2407-sup-0001-S1.pdf217K

Figure S1: Human autologous serum inhibits LTA-induced activation of human PBMC. Indicated concentrations of autologous sera were pre-incubated with WT-LTA or lgt-LTA for 1 h before addition of human PBMC from 3 healthy donors. Release of IL-1β was quantified in supernatants by ELISA. Data are shown as mean +SEM and are pooled from 3 experiments performed. Significant differences compared to the respective sample without ApoB100 were assessed by one-way ANOVA followed by Tukey's posttest, ***p<0.001, ###p<0.001.

Figure S2: Purified ApoB100 inhibits LTA-induced activation of human PBMC. Indicated concentrations of human ApoB100 were pre-incubated with WT-LTA or lgt-LTA for 1h before addition of human PBMC from 3 healthy donors. Release of IL-1β was measured in supernatants. Data are shown as mean +SEM and are pooled from 3 experiments performed. Significant differences compared to the respective sample without ApoB100 pre-incubation were assessed by one-way ANOVA followed by Tukey's posttest, *p<0.01, #p<0.01.

Figure S3: ApoA2 does not affect LTA-induced IL-1β release from human PBMC. Indicated concentrations of human ApoA2 were pre-incubated with lgt-LTA for 1h before addition of human PBMC from 4 healthy donors. Release of IL-1β was measured in the cell-free supernatant. Data are represented as mean +SEM and significant differences compared to the respective sample without ApoA2 pre-incubation were assessed by one-way ANOVA followed by Tuckey's posttest.

Table S1:Amount of circulating LDL in patients with hypercholesterolemia before as well as after ApoB100 apheresis

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.